Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study
Evan Morgan(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Julie Stephens(The Ohio State University), Anne M. Noonan(The Ohio State University), Zaibo Li(The Ohio State University Wexner Medical Center), Robert Wesolowski(The Ohio State University Wexner Medical Center), Nicole Williams(The Ohio State University), Gregory Young(The Ohio State University), Daniel G. Stover(Harvard University), Jeffrey VanDeusen(The Ohio State University), Joseph Liu(The Ohio State University Wexner Medical Center), Bhuvaneswari Ramaswamy(The Ohio State University), Mathew Cherian(The Ohio State University Wexner Medical Center), Raquel E. Reinbolt(The Ohio State University), Marilly Palettas(The Ohio State University Wexner Medical Center), Anupama Suresh(The Ohio State University Wexner Medical Center), Akaansha Ganju(Riverside Methodist Hospital), Sagar Sardesai(The Ohio State University), Amanda Luff(The Ohio State University Wexner Medical Center)
Cited by 31
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
|Nature|2016|629
Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells
|Proceedings of the National Academy of Sciences|2017|373
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296